Synthesis and biological evaluation of a novel series of 6,8-dibromo-4(3H)quinazolinone derivatives as anticancer agents.
Three novel series of 6,8-dibromo-4(3H)quinazolinone derivatives were synthesized. Some of the novel quinazolinone derivatives were tested for their antitumor activity against the human breast carcinoma cell line MCF-7. Compounds XIIIb, IX, XIVd, XIVb, XIVe, XIIIa, XIVc, XVc, and XIVa exerted powerful cytotoxic effects against the MCF7 cells, with very low IC50 values compared to doxorubicin (positive control). The IC50 values were 1.7, 1.8, 1.83, 5.4, 6.84, 10.8, 13.9, 15.7, and 29.6 µg/mL, respectively.